Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Hidetoshi Ehara"'
Publikováno v:
Heliyon, Vol 6, Iss 7, Pp e04138- (2020)
Background: Docetaxel is first-line chemotherapy for castration-resistant prostate cancer (CRPC), but most patients acquire docetaxel resistance. CD44 has been shown to be involved in drug resistance of cancers including prostate cancer. We hypothesi
Externí odkaz:
https://doaj.org/article/5b490c5b268d46d382383d6b64bd0252
Autor:
KOSUKE MIZUTANI, SEIJI SUGIYAMA, KOJI KAMEYAMA, SHINGO KAMEI, SHIGEAKI YOKOI, AKEMI MORIKAWA, MAKOTO TAKEUCHI, KENSAKU SEIKE, TORU YAMADA, HIDETOSHI EHARA, SEIYA SAWADA, KOUSEKI HIRADE, HIROHITO FURUTA, KENGO MATSUNAGA, TETSUYA YAMADA, IPPEI SAKAMOTO, YASUTAKA KATO, HIROSHI NISHIHARA, SATOSHI ISHIHARA, TAKASHI DEGUCHI
Publikováno v:
Cancer Genomics & Proteomics (1109-6535); Mar/Apr2024, Vol. 21 Issue 2, p203-212, 10p
Autor:
TAKU KATO, KYOJIRO KAWAKAMI, KOSUKE MIZUTANI, TATSUYA ANDO, YASUHIRO SAKAI, KOUHEI SAKURAI, SHOHEI TOYOTA, HIDETOSHI EHARA, HIROYASU ITO, MASAFUMI ITO
Publikováno v:
Cancer Genomics & Proteomics (1109-6535); Sep/Oct2023, Vol. 20 Issue 5, p456-468, 13p
Publikováno v:
Heliyon
Heliyon, Vol 6, Iss 7, Pp e04138-(2020)
Heliyon, Vol 6, Iss 7, Pp e04138-(2020)
Background Docetaxel is first-line chemotherapy for castration-resistant prostate cancer (CRPC), but most patients acquire docetaxel resistance. CD44 has been shown to be involved in drug resistance of cancers including prostate cancer. We hypothesiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adaf03546df0c8182e122ce7f3dcbfae
https://doi.org/10.1016/j.heliyon.2020.e04138
https://doi.org/10.1016/j.heliyon.2020.e04138
Autor:
Kosuke Mizutani, Riyako Terazawa, Hidetoshi Ehara, Yusuke Kanimoto, Yasunori Fujita, Keita Nakane, Masafumi Ito, Takashi Deguchi, Taku Kato, Yoshinori Nozawa, Toshio Kojima
Publikováno v:
Cytokine. 64:251-257
Castration-refractory prostate cancer (CRPC) is treated with taxane-based chemotherapy, but eventually becomes drug resistant. It is thus essential to identify novel therapeutic targets for taxane resistance in CRPC patients. We investigated the role
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9ad61e04e5f0c0a2368b6b13bf5ae97
https://doi.org/10.1016/j.cyto.2013.06.313
https://doi.org/10.1016/j.cyto.2013.06.313
Autor:
Mitsuhiro Taniguchi, Seiichi Kato, Toshimi Takeuchi, Naoki Yamamoto, Takashi Deguchi, Kunihiro Tsuchiya, Toru Yamada, Shingo Kamei, Hidetoshi Ehara
Publikováno v:
International Journal of Clinical Oncology. 15:271-279
Our aim was to provide nomograms that allow urologists to easily calculate a nonmuscle invasive bladder cancer patient’s risk of recurrence and progression. We retrospectively analyzed 800 nonmuscle invasive bladder cancer patients newly diagnosed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::212f92271a0f32b057c4e4bc0473105b
https://doi.org/10.1007/s10147-010-0049-6
https://doi.org/10.1007/s10147-010-0049-6
Autor:
Hidetoshi Ehara, Takashi Deguchi, Nguyen Ba Phuoc, Takahiro Goto, Masahiro Nakano, Naoki Yamamoto
Publikováno v:
Urology. 72:167-171
To identify predictive markers for biochemical failure after radical prostatectomy in patients with clinically confined prostate cancer.Immunohistochemistry of bcl-2, p53, Ki-67, and caveolin-1 was performed in samples of paraffin-embedded prostate c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462f36e868c9f66194788f3141cc4873
https://doi.org/10.1016/j.urology.2007.11.003
https://doi.org/10.1016/j.urology.2007.11.003
Autor:
Yasuaki Kubota, Takashi Deguchi, Hidetoshi Ehara, Osamu Tanaka, Shingo Kamei, Masahiro Nakano
Publikováno v:
International Journal of Urology. 15:322-326
Aim: Two-thirds of patients with a gray-zone prostate-specific antigen (PSA) level undergo unnecessary biopsy. Sensitivity is not yet sufficient to permit the use of modified PSA parameters or magnetic resonance (MR) imaging alone for prostate cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3931612dbb774841ee0c78b8e549fdbe
https://doi.org/10.1111/j.1442-2042.2008.01991.x
https://doi.org/10.1111/j.1442-2042.2008.01991.x
Autor:
Shingo Kamei, Shinichi Ito, Masanobu Horie, Kenichi Minoshima, Tsukasa Nagai, Toru Yamada, Yoji Moriyama, Hidetoshi Ehara, Hisao Komeda, Hideji Hayashi, Nariyasu Masue, Toshihiko Takada, Satoshi Ishihara, Takashi Deguchi, Tomohiro Tsuchiya
Publikováno v:
Nihon Toseki Igakkai Zasshi. 41:717-722
背景：二次性副甲状腺機能亢進症（SHPT）に対するマキサカルシトール（OCT）長期使用に関する報告は稀である．対象と方法：副甲状腺ホルモン（iPTH）が200pg/mLより高く，補正Ca（cCa）が1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d92d915deca9e542a63b768a5ddde9b7
https://doi.org/10.4009/jsdt.41.717
https://doi.org/10.4009/jsdt.41.717
Autor:
Hidenori Ito, Kosuke Mizutani, Koh-ichi Nagata, Takashi Deguchi, Yoshinori Nozawa, Hidetoshi Ehara
Publikováno v:
Cancer Biology & Therapy. 6:1800-1804
Vinexinbeta is an adaptor protein supposed to play pivotal roles in cell adhesion, cytoskeletal organization and signaling. Vinexinbeta is reported to be phosphorylated by extracelluler signal-regulated kinase (ERK) and the phosphorylation has been s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f0fc221cfbdc6feea9290dbbadd60bf
https://doi.org/10.4161/cbt.6.11.4862
https://doi.org/10.4161/cbt.6.11.4862